Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Estimands for overall survival in clinical trials with treatment switching in oncology.
Manitz J, Kan-Dobrosky N, Buchner H, Casadebaig ML, Degtyarev E, Dey J, Haddad V, Jie F, Martin E, Mo M, Rufibach K, Shentu Y, Stalbovskaya V, Sammi Tang R, Yung G, Zhou J. Manitz J, et al. Among authors: stalbovskaya v. Pharm Stat. 2022 Jan;21(1):150-162. doi: 10.1002/pst.2158. Epub 2021 Oct 3. Pharm Stat. 2022. PMID: 34605168
Response to comments on "Properties of the weighted log-rank test in the design of confirmatory studies with delayed effects" by José L. Jiménez, Viktoriya Stalbovskaya and Byron Jones, Pharmaceutical Statistics, 2019; 18:287-303, DOI: 10.1002/pst.1923.
Jiménez JL, Stalbovskaya V, Jones B. Jiménez JL, et al. Among authors: stalbovskaya v. Pharm Stat. 2020 Sep;19(5):736-740. doi: 10.1002/pst.2021. Epub 2020 Apr 5. Pharm Stat. 2020. PMID: 32248622 No abstract available.
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.
Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, Cervantes F, Jones MM, Sun K, McQuitty M, Stalbovskaya V, Gopalakrishna P, Barbui T. Harrison CN, et al. Among authors: stalbovskaya v. Leukemia. 2016 Aug;30(8):1701-7. doi: 10.1038/leu.2016.148. Epub 2016 May 23. Leukemia. 2016. PMID: 27211272 Free PMC article. Clinical Trial.
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.
Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S; COMFORT Investigators. Vannucchi AM, et al. Among authors: stalbovskaya v. Haematologica. 2015 Sep;100(9):1139-45. doi: 10.3324/haematol.2014.119545. Epub 2015 Jun 11. Haematologica. 2015. PMID: 26069290 Free PMC article. Clinical Trial.
Ruxolitinib is an effective treatment for CALR-positive patients with myelofibrosis.
Guglielmelli P, Rotunno G, Bogani C, Mannarelli C, Giunti L, Provenzano A, Giglio S, Squires M, Stalbovskaya V, Gopalakrishna P, Vannucchi AM; COMFORT-II Investigators. Guglielmelli P, et al. Among authors: stalbovskaya v. Br J Haematol. 2016 Jun;173(6):938-40. doi: 10.1111/bjh.13644. Epub 2015 Aug 25. Br J Haematol. 2016. PMID: 26303809 Free article. Clinical Trial. No abstract available.
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G. Harrison C, et al. Among authors: stalbovskaya v. N Engl J Med. 2012 Mar 1;366(9):787-98. doi: 10.1056/NEJMoa1110556. N Engl J Med. 2012. PMID: 22375970 Free article. Clinical Trial.
16 results